chufangao/CTO huggingface dataset:
Clinical trial NCT03689946: Effect of Evolocumab on Coronary Atherosclerosis
Official title: Effect of Evolocumab on Coronary Artery Plaque Volume and Composition by Coronary CTA (CCTA) and Microcalcification by F18-NaF PET: A Phase 3 Study
Sponsor: Cedars-Sinai Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 55.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-19
Primary completion date: 2023-01-28
Completion date: 2023-05-30
Baseline population: Of the 55 patients initially enrolled, 3 were lost to follow-up, 3 withdrew consent, and 2 were not included in analysis due to missing imaging information
Limitations and caveats: 1. The sample size is small, and the study population was selectively chosen based on baseline plaque burden.~2. Because inclusion criteria focused on plaque burden, the predominantly male population, known to have higher plaque burden, limits the generalizability of the findings.~3. As a single-arm study, the absence of a comparison group receiving statin only treatment or a control group receiving no treatment limits the ability to draw direct comparisons.
Plan to share individual participant data: NO
Clinical trial NCT03578354: 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
Official title: Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine
Sponsor: Massachusetts Eye and Ear Infirmary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funding not acquired
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-01-31
Primary completion date: 2023-01-31
Completion date: 2024-08-31
Clinical trial NCT00753545: Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
Official title: Phase II Randomised, Double Blind, Multicentre Study to Assess the Efficacy of AZD2281 in the Treatment of Patients With Platinum Sensitive Relapsed Serous Ovarian Cancer Following Treatment With Two or More Platinum Containing Regimens
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 265.0 (ACTUAL)
Number of arms: 2.0
Start date: 2008-08-28
Primary completion date: 2010-06-30
Completion date: 2023-10-12
Limitations and caveats: For OM DoR: The subset of patients evaluable for response who responded to study treatment.Values in results table may be under-estimates as some patients had not progressed at final analysis,so true duration is likely to be greater than in database.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04464512: Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population
Official title: Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population
Acronym: SUPER-ERAS
Sponsor: West Virginia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No qualified enrollments; study cancelled due to pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-10
Primary completion date: 2021-08-22
Completion date: 2021-08-22
Clinical trial NCT04570449: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)
Official title: Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Study timeline is not feasible
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-30
Primary completion date: 2021-11-30
Completion date: 2021-12-31
Clinical trial NCT02938013: deLIVER: Direct Acting Antiviral Effects on the Liver
Official title: deLIVER: Direct Acting Antiviral Effects on the Liver
Acronym: deLIVER
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-01-31
Primary completion date: 2019-09-30
Completion date: 2020-09-30
Limitations and caveats: This study is based on a relatively small sample of the liver
Plan to share individual participant data: NO
Clinical trial NCT03059563: Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
Official title: Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Global pandemic
Enrollment: 62.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-11
Primary completion date: 2023-09-28
Completion date: 2023-09-28
Clinical trial NCT04758949: FL-101 in Surgically Resectable Non-Small Cell Lung Cancer
Official title: A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer
Sponsor: Flame Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-25
Primary completion date: 2021-12-22
Completion date: 2021-12-22
Clinical trial NCT04492475: Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
Official title: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 969.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-05
Primary completion date: 2020-12-21
Completion date: 2020-12-21
Clinical trial NCT02226159: Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain
Official title: Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain (SPIES): a Randomized, Controlled Trial
Acronym: SPIES
Sponsor: OrthoCarolina Research Institute, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: insufficient data for data publication
Enrollment: 65.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-08-31
Primary completion date: 2019-05-31
Completion date: 2024-12-31
Clinical trial NCT03334578: The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients.
Official title: The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients.
Sponsor: Lawson Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of recruitment
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-03
Primary completion date: 2020-12-17
Completion date: 2020-12-17
Plan to share individual participant data: NO
Clinical trial NCT02229149: Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Official title: Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)
Sponsor: US Oncology Research (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: per Sponsor request
Enrollment: 33.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-12-31
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Clinical trial NCT03535272: Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea
Official title: Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance Genes
Sponsor: Centers for Disease Control and Prevention (FED)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Unable to reach target sample size.
Enrollment: 281.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-20
Primary completion date: 2023-11-01
Completion date: 2023-12-31
Plan to share individual participant data: NO
Clinical trial NCT03936192: A Parallel-group Active Comparator, Double-blind, Multicenter, Randomized, Double-blind, Phase III Clinical Study
Official title: Parallel-group Active Comparator, Double-blind, Randomized, Phase III Study to Assess Safety, Efficacy of Glucosamine Sulfate Plus Meloxicam vs Glucosamine Sulfate Plus Chondroitin Sulfate Primary Symptomatic Knee Osteoarthritis Treatment
Acronym: SAVE
Sponsor: Eurofarma Laboratorios S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Company decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-01-31
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: NO
IPD sharing description: It is not yet known if there will be a plan to make IPD available.
Clinical trial NCT03697603: A Study of Brexpiprazole in Patients With Major Depressive Disorder
Official title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial to Assess the Efficacy and Safety of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder
Sponsor: Otsuka Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 740.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-30
Primary completion date: 2022-06-06
Completion date: 2022-07-04
Baseline population: Full Analysis Set (FAS) which comprised subjects who, after randomization, had received at least 1 dose of the study medication in the double-blind period (Phase B), and from whose the Montgomery Åsberg Depression Rating Scale (MADRS) total scores had been obtained at baseline and at least 1 time point after initiation of the treatment.
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Clinical trial NCT03547167: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1515.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-16
Primary completion date: 2020-01-20
Completion date: 2020-01-20
Baseline population: All randomized participants who received at least 1 dose of study vaccination.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05494866: A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma
Official title: IntenSify: An Open-label Phase I Trial of the CYP3A Inhibitor Cobicistat and the Cytostatics Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma to Evaluate the Combination's Pharmacokinetics, Safety and Efficacy
Acronym: IntenSify
Sponsor: German Cancer Research Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: lack of efficacy paired with high toxicity
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-12-07
Primary completion date: 2024-03-15
Completion date: 2024-03-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03129776: Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer
Official title: Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer for Treatment With Definitive Chemoradiation Therapy
Sponsor: Sunnybrook Health Sciences Centre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of participants
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-13
Primary completion date: 2022-09-15
Completion date: 2022-09-15
Plan to share individual participant data: NO
Clinical trial NCT03370510: Translating Neuroprediction Into Precision Medicine Via Brain Priming
Official title: Translating Neuroprediction Into Precision Medicine Via Brain Priming
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Covid-19 Pandemic
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-12-07
Primary completion date: 2021-07-28
Completion date: 2021-07-28
Limitations and caveats: This study was terminated early due to issues related to the covid-19 pandemic. Only 3 participants completed the trial- 1 out of 3 in the oxytocin group and 2 in the placebo group. As such, the mean score for the oxytocin group is based off of one subjects data only.
Clinical trial NCT04855591: A Trial of SHR-1703 in Healthy Subjects
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, PK, PD and Immunogenicity of Single Subcutaneous Administered SHR-1703 in Healthy Caucasian Subjects
Sponsor: Atridia Pty Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Adjustment of the clinical development plan for this product globally
Enrollment: 1.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-06-14
Primary completion date: 2021-09-13
Completion date: 2021-11-18
Plan to share individual participant data: NO
Clinical trial NCT02927249: Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
Official title: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Sponsor: Alliance for Clinical Trials in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: DSMB review
Enrollment: 3021.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-08
Primary completion date: 2021-12-13
Completion date: 2023-02-15
Clinical trial NCT02433587: Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization
Official title: Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization
Sponsor: University Hospitals Cleveland Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Never recruited any patients.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-31
Primary completion date: 2021-07-31
Completion date: 2023-07-31
Clinical trial NCT05017454: Sodium Valproate-loaded Nanospanlastics in Patchy Alopecia Areata in Comparison to Topical Steroids
Official title: Assessment of Efficacy and Safety of Sodium Valproate -Loaded Nanospanlastics in Patients With Patchy Alopecia Areata in Comparison to Conventional Therapy With Topical Steroids: a Randomized Controlled Study, With Clinical, Dermoscopic and Molecular Asessements
Sponsor: Kasr El Aini Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 67.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-01
Primary completion date: 2023-01-01
Completion date: 2023-04-01
Plan to share individual participant data: NO
Clinical trial NCT04339595: Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis
Official title: A Phase IV Interventional Study to Assess the Disease-Modifying Effect of Long-Term Treatment With Tildrakizumab in Adult Patients With Moderate-To-Severe Plaque Psoriasis (MODIFY)
Acronym: MODIFY
Sponsor: Almirall, S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Low Recruitment
Enrollment: 47.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-29
Primary completion date: 2020-07-31
Completion date: 2020-07-31
Clinical trial NCT04044781: A Phase 1, Open-Label, PET Study of T2310 & BPN14770
Official title: A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of BPN14770
Sponsor: Tetra Discovery Partners (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Change in Research Direction
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-10
Primary completion date: 2020-04-30
Completion date: 2020-05-30
Plan to share individual participant data: NO
Clinical trial NCT03335488: Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
Official title: A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-20
Primary completion date: 2022-07-05
Completion date: 2022-12-20
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT02417974: Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
Official title: Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
Acronym: FMT
Sponsor: Boston Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment was exacerbated by a covid policy related study suspension so the research was stopped.
Enrollment: 24.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-09-30
Primary completion date: 2021-02-04
Completion date: 2021-02-04
Limitations and caveats: Low enrollment was exacerbated by a covid policy related study suspension so the research was stopped.
Plan to share individual participant data: NO
Clinical trial NCT04864782: QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Official title: A Study of QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Sponsor: Qilu Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Phase 2 completed, phase 3 sponsor decided to terminate
Enrollment: 46.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-23
Primary completion date: 2022-09-30
Completion date: 2023-11-01
Clinical trial NCT03522259: Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery
Official title: BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery
Acronym: BARIVA
Sponsor: Insel Gruppe AG, University Hospital Bern (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 272.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-19
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Clinical trial NCT04226456: Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
Official title: Clinical Trial: Intratympanic Injection of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity
Sponsor: Centre Hospitalier Universitaire Saint Pierre (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: poor recruitment
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-10
Primary completion date: 2023-05-03
Completion date: 2023-09-03
Clinical trial NCT03998592: Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes
Official title: Phase I Clinical Trial for Assessment of Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes in Healthy Volunteers
Sponsor: Butantan Institute (OTHER_GOV)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Agreement between interested partied ended
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-05-31
Primary completion date: 2022-03-31
Completion date: 2023-10-31
Plan to share individual participant data: NO